Platelet Indices Altered in Severe Malaria
|
By LabMedica International staff writers Posted on 08 Jan 2014 |

Image: Photomicrograph shows a growing Plasmodium vivax trophozoite in a blood smear (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Changes in platelet counts during acute malaria are common and such changes are a major cause of concern to clinicians because such cases are more likely to evolve into serious and complicated disease.
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
The reduction in the number of platelets, platelet function is also compromised in these patients suffering from acute malaria infection and this is generally evidenced by changes in the volume and other features of platelet cells.
Scientists at the University Hospital of Federal University of Mato Grosso (Cuiabá, Brazil) performed a cross-sectional descriptive study based on the clinical and laboratory data of 186 patients with acute malaria caused by Plasmodium vivax who attended the Malaria Clinic between 2008 and 2013. All the patients underwent hemogram and blood biochemical analyses at their first appointment and malaria was diagnosed on the basis of the microscopic examination of Giemsa-stained thick smears.
All blood cell counts were determined using the Pentra 80 automated equipment (Horiba Medical; Montpellier, France), which provides results for mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The normal ranges for MPV, PDW, and PCT provided for this equipment are 7.0/µm3–10.5/µm3, 11%–18%, and 0.15%–0.50% respectively. Patients with a longer duration of symptoms or those identified as primo infected were considered potential candidates for evolution into the severe form of malaria.
The MPV, PDW, and PCT values exhibited significant variability. A significant inverse relationship was observed between parasitaemia and PCT. Patients with warning signs for evolution into severe disease, with primo infection, or presenting with symptoms for over three days had the highest MPV and PDW. The mean platelet count was 114,823 ± 76,761 cells/mm3; 16.7% of the patients exhibited counts fewer than 50,000/mm3 and 60.7% had platelet counts between 50,000/mm3 and 150,000/mm3. The mean MPV was 9.3 µm, the mean PDW was 17.5% and mean PCT was 0.104%. Potentially more serious cases, that is, primo-infected patients, exhibited significantly higher MPV and PDW.
The authors concluded that that platelet indices were altered during acute and symptomatic infection by P. vivax. The elevation of MPV and PDW, and reduction of PCT are related to known potential risk factors for evolution into severe malaria, such as primo infection, longer symptom duration, and the presence of the classical warning signs of severe and complicated P. falciparum malaria. Therefore, these parameters and indices could be useful as predictors of severity in the clinical approach of patients with malaria caused by P. vivax. The study was published on December 27, 2013, in the Malaria Journal.
Related Links:
University Hospital of Federal University of Mato Grosso
Horiba Medical
Latest Hematology News
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








